|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
90,552,000 |
Market
Cap: |
3.34(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$18.07 - $44.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 8 |
Insider 3/6 Months : 8.6 |
|
Guru Rank Number : 538 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
26,156 |
72,347 |
85,013 |
300,515 |
Total Sell Value |
$921,768 |
$2,218,045 |
$2,727,877 |
$13,658,321 |
Total People Sold |
4 |
9 |
10 |
16 |
Total Sell Transactions |
6 |
28 |
30 |
90 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pauwels Eric |
Chief Business Officer |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
16,800 |
51,320 |
|
- |
|
Pauwels Eric |
Chief Business Officer |
|
2022-01-07 |
4 |
S |
$38.53 |
$33,363 |
D/D |
(866) |
34,520 |
|
17% |
|
Reeve Emma |
Director |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
7,528 |
|
- |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
15,600 |
37,933 |
|
- |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2022-01-07 |
4 |
S |
$38.53 |
$30,820 |
D/D |
(800) |
22,333 |
|
17% |
|
Schmertzler Michael |
Director |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
6,400 |
109,766 |
|
- |
|
Steele Glenn Jr Md |
Director |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
6,500 |
|
- |
|
Utter Christine Marie |
SVP, Finance & CAO |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
11,600 |
27,853 |
|
- |
|
Utter Christine Marie |
SVP, Finance & CAO |
|
2022-01-07 |
4 |
S |
$38.53 |
$28,778 |
D/D |
(747) |
16,253 |
|
17% |
|
Boulding Mark Elliott |
Exec. VP and CLO |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,400 |
61,889 |
|
- |
|
Boulding Mark Elliott |
Exec. VP and CLO |
|
2022-01-07 |
4 |
S |
$38.53 |
$34,095 |
D/D |
(885) |
47,489 |
|
17% |
|
Southwell David P |
Director |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
6,500 |
|
- |
|
Jacobson Allan Steven |
Director |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
8,348 |
|
- |
|
Zeldis Jerome B |
Director |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
6,500 |
|
- |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
I/I |
780 |
2,490 |
|
- |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2022-01-07 |
4 |
S |
$38.53 |
$1,734 |
I/I |
(45) |
1,710 |
|
17% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
14,400 |
49,458 |
|
- |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2022-01-07 |
4 |
S |
$38.53 |
$29,125 |
D/D |
(756) |
35,058 |
|
17% |
|
Okey Stephanie |
Director |
|
2022-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,200 |
4,163 |
|
- |
|
Hill Emily Luisa |
Chief Financial Officer |
|
2022-01-04 |
4 |
S |
$41.16 |
$7,121 |
D/D |
(173) |
23,133 |
|
23% |
|
Peltz Stuart Walter |
Chief Executive Officer |
|
2022-01-04 |
4 |
S |
$41.16 |
$15,559 |
I/I |
(378) |
22,834 |
|
23% |
|
Pauwels Eric |
Chief Business Officer |
|
2022-01-04 |
4 |
S |
$41.16 |
$33,177 |
D/D |
(806) |
35,386 |
|
23% |
|
Almstead Neil Gregory |
Chief Technical Ops Officer |
|
2022-01-04 |
4 |
S |
$41.16 |
$2,634 |
I/I |
(64) |
1,755 |
|
23% |
|
Boulding Mark Elliott |
Exec. VP and CLO |
|
2021-09-02 |
4 |
AS |
$45.01 |
$151,375 |
D/D |
(3,363) |
48,374 |
|
-5% |
|
Boulding Mark Elliott |
Exec. VP and CLO |
|
2021-09-02 |
4 |
OE |
$18.01 |
$60,568 |
D/D |
3,363 |
51,737 |
|
- |
|
524 Records found
|
|
Page 8 of 21 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|